EAM
CHRS icon

EverPoint Asset Management’s Coherus Oncology CHRS Stock Holding History

EverPoint Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.81M Buy
+100,000
New +$2.8M 0.05% 303
2016
Q2 		– Sell
-50,000
Closed -$1.06M – 394
2016
Q1 		$1.06M Buy
+50,000
New +$819K 0.02% 378

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

EverPoint Asset Management's CHRS Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Coherus Oncology (CHRS) in Q4 2016: 100,000 shares worth $2.81M. The stake represents 0.05% of the portfolio and ranks #303 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in CHRS as recently as Q1 2016.

EverPoint Asset Management first reported a position in CHRS in Q1 2016 and has held it in 2 quarters since. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

  • EverPoint Asset Management held 100,000 shares of Coherus Oncology worth $2.81M as of Q4 2016.
  • Coherus Oncology was a new EverPoint Asset Management position in Q4 2016.
  • Coherus Oncology made up 0.05% of EverPoint Asset Management's portfolio in Q4 2016, its #303 holding.
  • EverPoint Asset Management first reported a position in Coherus Oncology in Q1 2016 and has held it in 2 quarters since.
  • 122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.